Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
复制标题
DOI：
10.1200/jco.2005.06.150
复制
发表时间：
2005-09-01
影响因子：
45.3
通讯作者：
Vercammen, E
中科院分区：
文献类型：
--
作者：
Leyland-Jones, B;Semiglazov, V;Vercammen, E
目的 评估接受一线化疗的转移性乳腺癌 (MBC) 女性患者，使用阿法依泊汀与安慰剂将血红蛋白 (Hb) 维持在 12 至 14 g/dL 范围内对生存和生活质量的影响。 患者和方法 符合条件的患者被随机分配接受每周一次阿法依泊汀 40,000 U 或安慰剂，为期 12 个月。如果基线 Hb 为
Purpose To evaluate the effect on survival and quality of life of maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with epoetin alfa versus placebo in women with metastatic breast cancer (MBC) receiving first-line chemotherapy.Patients and Methods Eligible patients were randomly assigned to receive epoetin alfa 40,000 U once weekly or placebo for 12 months. Study drug was initiated if baseline Hb was